Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Takeda, Hutchmed hook up on cancer drug for $1.13B
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(548)
•••
Comment by Rumpl3StiltSkinon Jan 24, 2023 11:27am
161 Views
Post# 35242363

RE:RE:RE:RE:RE:Takeda, Hutchmed hook up on cancer drug for $1.13B

RE:RE:RE:RE:RE:Takeda, Hutchmed hook up on cancer drug for $1.13B
Yajne wrote: Great dialog regarding TLT's potential on TLD 1433 for which I am extremely optimistic! However, can any of these possible deals be concluded during Q1 which would eliminate funding concern? Or maybe $400K/mo burn rate has dropped due to events that we're not aware of, deferred salaries or similar? ...which would have the effect of extending the timing. JMHO DYODD. Any expert thoughts on this?

Rumpl3StiltSkin wrote: Ok, I was thinking TLT might make a similar deal for 1433, then keep the other Osmium/Iridium based PDCs to go after Brain, Lung, Breast, etc. Would certainly bring in a ton of money.




Yajne, I'm still thinking they have enough $$ to get to the BTD and possibly AA position that they 'should' be in by July... SP  'should' be much better then and so will all possible venues for funding.

IF they need funds sooner they could just do another smallish PP, right?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities